EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered Trivalent Human IgG1-Fc Proteins for Potent Complement Inhibition

Ian K Campbell iD, Daniel Ortiz, Carlos Bosques, Matthew P Hardy iD, Andrea Tester, Vesna Tomasetig, Daniel Couto iD, Thomas Gentinetta iD, Sabine Pestel iD, Padmapriya Ponnuswamy iD, Fabian Käsermann iD, Rolf Spirig

Cells · 25.06.2026 · 15 (13) · 1156

DOI: 10.3390/cells15131156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 25.06.2026. Verfasst von Ian K Campbell und 11 weiteren Autor:innen. Beteiligte Einrichtung: CSL Limited, Bio21 Institute, 30 Flemington Rd., Parkville, VIC 3010, Australia. Hauptthemen laut MEDLINE: Immunoglobulin G, Immunoglobulin Fc Fragments, Complement C1q, Protein Engineering. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-dose intravenous immunoglobulin (IVIG) is used to treat autoimmune and inflammatory diseases, and several studies demonstrate that the therapeutic effects of IVIG can be recapitulated with the fragment crystallizable (Fc) portion. Further, recent data indicate that recombinant multimeric Fc molecules exhibit potent anti-inflammatory properties. In this study, we investigated the biochemical and biological properties of different recombinant human IgG1 Fc molecules with increasing valency and avidity, combined with mutations to increase binding affinity to complement protein C1q. These molecules were investigated for their potential dual antagonism: to antagonize Fcγ receptor (FcγR) effector functions (Ab-dependent cellular phagocytosis) in vitro, and to inhibit the activation of the classical complement pathway. C1q-binding mutants demonstrated an exponential increase in potency to inhibit the classical pathway in correlation with increasing multimerization. Importantly, in contrast to other multimeric Fc constructs such as Fc hexamers, no generation of complement C4a was observed. Reducing the binding affinity to FcγRIIB resulted in a half-life extension of the trivalent hIgG1-Fc molecules in human neonatal Fc receptor transgenic (hFcRn Tg) mice. Our data demonstrate a potent anti-inflammatory effect of recombinant human IgG1-Fc C1q-binding mutants in vitro and in vivo, mediated by blockade of FcγRs and inhibition of complement activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GImmunoglobulin Fc FragmentsComplement C1qProtein EngineeringHumansAnimalsReceptors, FcMiceMice, TransgenicComplement ActivationProtein BindingReceptors, IgGPhagocytosisHistocompatibility Antigens Class I

Stichwörter der Autor:innen

Fc receptorscomplementinnate immunity

Substanzen

Immunoglobulin GImmunoglobulin Fc FragmentsComplement C1qReceptors, FcFc receptor, neonatalReceptors, IgGHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • CSL Limited, Bio21 Institute, 30 Flemington Rd., Parkville, VIC 3010, Australia.
  • Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA.
  • CSL Behring Biologics Research Center, Swiss Institute for Translational and Entrepreneurial Medicine, 3010 Bern, Switzerland.
  • CSL Behring GmbH, 35041 Marburg, Germany.

ORCID-Profile: Ian K Campbell, Matthew P Hardy, Daniel Couto, Thomas Gentinetta, Sabine Pestel, Padmapriya Ponnuswamy, Fabian Käsermann

Zitieren

APA

Campbell, I. K., Ortiz, D., Bosques, C., Hardy, M. P., Tester, A., Tomasetig, V., Couto, D., Gentinetta, T., Pestel, S., Ponnuswamy, P., Käsermann, F., & Spirig, R. (2026). Engineered Trivalent Human IgG1-Fc Proteins for Potent Complement Inhibition. Cells, 15(13), 1156. https://doi.org/10.3390/cells15131156

Vancouver

Campbell IK, Ortiz D, Bosques C, Hardy MP, Tester A, Tomasetig V, et al. Engineered Trivalent Human IgG1-Fc Proteins for Potent Complement Inhibition. Cells. 2026;15(13):1156. doi:10.3390/cells15131156

BibTeX
@article{Campbell2026,
  author = {Campbell, Ian K and Ortiz, Daniel and Bosques, Carlos and Hardy, Matthew P and Tester, Andrea and Tomasetig, Vesna and Couto, Daniel and Gentinetta, Thomas and Pestel, Sabine and Ponnuswamy, Padmapriya and Käsermann, Fabian and Spirig, Rolf},
  title = {Engineered Trivalent Human IgG1-Fc Proteins for Potent Complement Inhibition},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {1156},
  doi = {10.3390/cells15131156}
}
Kostenlos starten →